AMEND news in Tag: neuroendocrine cancer

• AMEND Represents GenNETS Internationally

  

  From 7-8 September, AMEND CEO, Jo Grey, represented our Genetic Neuroendocrine Tumour Syndrome (GenNETS) patient communities at the annual summit of the International Neuroendocrine Cancer Alliance in Sofia, Bulgaria.

  Click here for more information

• NETS in RETS

  

  November 10th each year is NET Cancer Day, initiated by the International Neuroendocrine Cancer Alliance, of which AMEND is a member representing genetic neuroendocrine tumour syndromes.  To better explain the link between NETs and RETS (rare endocrine tumours and syndromes), join us for our webinar, NETs in RETS, with Professor Karim Meeran on Thursday 9th November from 18:00-19:00.

  Click here for more information

• Archived news
• 2026
• 2025
• 2024
• 2023
• 2022
• 2021
• 2020
• 2019
• 2018
• 2017
• 2016